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Passively transferred human NMO-IgG
exacerbates demyelination in mouse
experimental autoimmune encephalomyelitis
Harleen Saini1, Robert Rifkin1, Michael Gorelik1, Hwa Huang1,2, Zachary Ferguson1,2, Melina V Jones1
and Michael Levy1,2*
Abstract
Background: Neuromyelitis optica (NMO) is a devastating inflammatory disorder of the optic nerves and spinal
cord characterized by frequently recurring exacerbations of humoral inflammation. NMO is associated with the
highly specific NMO-IgG biomarker, an antibody that binds the aquaporin-4 water channel. Aquaporin-4 is present
on glial endfeet in the central nervous system (CNS). In humans, the NMO-IgG portends more frequent
exacerbations and a worse long-term clinical outcome.
Methods: We tested the longer-term outcome of mice with EAE injected with NMO-IgG and followed them for 60
days. Clinical exams and pathology of the spinal cord and optic nerves were compared to mice that received
control human IgG.
Results: Passively transferred human NMO-IgG leads to more severe neurology disability over two months after
onset of disease. Clinical worsening is associated with an increased concentration of large demyelinating lesions
primarily to subpial AQP4-rich regions of the spinal cord.
Conclusions: NMO-IgG is pathogenic in the context of EAE in mice.
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Background
Neuromyelitis optica (NMO) is a devastating neuro-
inflammatory disorder that preferentially targets the optic
nerves, brainstem and spinal cord [1]. Also known as
Devic’s disease, NMO is associated with the highly specific
NMO-IgG antibody found in up to 63% of patients [2].
The target of the NMO-IgG is the aquaporin-4 (AQP4)
water channel expressed in multiple tissues in the body.
AQP4 is the major aquaporin found in the CNS and is
highly localized to the endfeet of astrocytes, especially
along the pia limitans and on the abluminal surface of
blood vessels in the brain [3].
The NMO-IgG is hypothesized to be pathogenic; bind-
ing of the antibody to its glial target triggers a humoral
inflammatory cascade involving IgG, IgM, complement
deposition and recruitment of neutrophils and eosinophils
[4]. This model of disease is supported by two reports of
passively transferred NMO-IgG in which the NMO-IgG
exacerbates behavioral signs of rat experimental auto-
immune encephalomyelitis (EAE) and induces a pathology
similar to human NMO: areas of acute inflammation with
granulocytes, a dramatic loss of aquaporin-4 staining and
complement deposition [5,6]. While EAE induced by mye-
lin basic protein in complete Freund’s adjuvant (CFA) in
Lewis rats generally leads to a complete neurologic recov-
ery [7], EAE induced by myelin oligodendrocyte glycopro-
tein peptide 35–55 (MOG35-55) in C57Bl6 mice causes
demyelination and axon loss in the spinal cord with limited
behavioral recovery, the latter of which may better repre-
sent a more suitable animal model system for severe hu-
man neuromyelitis optica disease.
One of the hallmarks of the NMO-IgG seropositive
testing in humans with NMO disease is the prognostic
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implication of more frequent recurrences and worse
neurologic outcome with increased disability compared
to individuals with NMO whose serum does not react
with AQP4 [8]. In our study, we tested the consequences
of NMO-IgG in mouse EAE passively transferred at dis-
ease onset on long-term outcome and found that the
NMO-IgG results in a worse neurological outcome which
is maintained as late as two months after immunization.
Pathological evaluation revealed larger, primarily subpial
demyelinated lesions in the spinal cord and optic nerves
of EAE mice receiving passively transferred NMO-IgG.
Methods
Animals
Adult female C57/BL6 mice between 6 – 8 weeks of
age were purchased from The Jackson Laboratory and
housed in a 12-hour artificial light–dark cycle and had ad
libitum access to food and water. The Johns Hopkins
Institutional Animal Care and Use Committee approved
all experimental procedures.
Samples
Human IgG fractions were purified from the plasma of
patients undergoing plasma exchange using a resin based
purification method (Melon Gel IgG Purification kit,
Thermo Scientific) two days prior to injection. The puri-
fied IgG was concentrated by spin column centrifugation
(Amicon Ultra, 100kD MW cut off ) and the final protein
concentration was adjusted to 25 mg/ml for 100 μl intra-
peritoneal injection. All NMO patients tested seroposi-
tive for the NMO-IgG by the Mayo clinical NMO-IgG
assay and the NMO plasma samples from 3 patients were
pooled prior to purification. Human control IgG fraction
(control-IgG) was obtained from a non-NMO patient
undergoing plasma exchange for ABO incompatibil-
ity. All samples were obtained through a protocol ap-
proved by the Johns Hopkins Institutional Review Board
(NA_ 00003551) in a de-identified manner with informed
consent to use the samples for research.
EAE induction and scoring
Experimental autoimmune encephalomyelitis (EAE) was
induced in 3 groups of 10 mice. Each animal received a
single subcutaneous injection of one hundred microliters
of an emulsified solution of 1:1, 5 mg/ml Myelin Oligo-
dendrocyte Glycoprotein (MOG) peptide 35–55 in phos-
phate buffered saline (PBS) and incomplete Freund’s
adjuvant containing 12.5 mg/ml heat-killed Mycobacter-
ium tuberculosis; each animal therefore received 250 μg
MOG35-55 and 625 μg M. tuberculosis (day 0). Pertussis
Toxin (300 ng) was administered intraperitoneally on
days 0 and 2. Animals were weighed daily and scored on
a standardized 5-point EAE disability scale by a blinded
examiner [9]. A series of 4 intraperitoneal injections of
human IgG purified from either pooled NMO plasma or
control human plasma were administered on days 13, 14,
18, and 19 for a total of 10 mg/animal [5], with the initial
pair of injections corresponding to onset of EAE disease
and the second pair of injections provided during the ini-
tial remission of EAE. Vehicle controls received an equal
volume of PBS.
Tissue processing and histology
Animals were anesthetized with isofluorane and perfused
via cardiac puncture first with PBS and then with freshly
prepared 4% formaldehyde solution. The optic nerves and
spinal cords were harvested, fixed overnight, cryopreserved
in 30% sucrose and frozen for sectioning. After embedding
tissue in in O.C.T. Compound (Tissue-Tek® ), ten to thirty
micron slices sections were mounted on Superfrost Plus
Microscope Slides (Fisher brand). The first cohort of ani-
mals was sacrificed 20 minutes after the last intraperitoneal
injection of human IgG for the purpose of tracking human
antibody entrance into the mouse central nervous system.
The second cohort of animals was sacrificed and their
tissue was prepared in a similar fashion on day 62 post-
EAE induction.
Eriochrome cyanine staining for myelin
Eriochrome cyanine was used to identify demyelinating le-
sions in the sectioned tissue. Slides with frozen sections
were thawed at room temperature. Eriochrome cyanine so-
lution was prepared by dissolving eriochrome cyanine in
450 ml 0.5% H2SO4(0.2%) and 10% FeCl3 added to a final
concentration of 0.4%. The sectioned tissue was hydrated
by serial washes in 100% ethanol, 95% ethanol, 70% ethanol
and distilled water for 10 minutes each and then immersed
for 15 minutes in eriochrome cyanine solution. After stain-
ing, differentiation was carried out in freshly made 0.1%
NH4OH for 20–30 seconds and halted by thorough wash-
ing in distilled water. Slides were mounted as described in
the preceding section.
Immunohistochemistical staining
Immunohistochemical staining was performed by im-
mersing 20–30 μm sections of mouse CNS tissue in
blocking solution for 2 hours at room temperature as indi-
cated in Table 1 before incubation with primary antibody
overnight at 4°C. Sections were then washed three times in
PBS prior to incubation with a secondary antibody conju-
gated with either Alexa Fluor 488 or 555 (Invitrogen) at
room temperature for 1 hour. Slides were then washed and
mounted with fluorescence mounting media (Dako) or
Fluoro-gel (Electron Microscopy Sciences).
Myelin quantification
Six to eight areas of eriochrome-stained spinal cord were
photographed at high resolution (4080x3072) using a 4x
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objective and background corrected to correct for uneven
illumination. Image analysis was performed in a blinded
fashion. Using ImageProPlus5 software, two measurements
were acquired from each image: (1) a total measure of
the white matter area (including eriochrome-stained re-
gions and demyelinated areas) and (2) a measure of each
demyelinated lesion’s area, outlined as separate areas of
interest (AOIs). During analysis, each lesion was noted to
be largely bordered by the pia mater or not; while most
EAE lesions contact the pia, this analysis was to indicate
lesions whose major axis contacted the pia. For total
demyelinated area, lesioned areas were summed. For per-
cent demyelinated area, this measure was divided by the
total white matter area. “Large pial lesions” were classi-
fied as those comprised of ≥10,000μm2. For percent large
pial lesions, the total area of these large lesions was di-
vided by the total demyelinated area for that animal to
demonstrate the prevalence of these large subpial conflu-
ent lesions in these mice. For percent pial lesions, the
area of all lesions blindly classified as primarily pial was
summed and divided by the total demyelinated area for
that animal.
Statistics
For comparison of EAE scores, a non-parametric (Mann–
Whitney U-test) was performed. For comparison of
demyelinated areas, Student t-tests were performed. Data
was analyzed and depicted using GraphPad 5.0 software.
Results were deemed statistically significant for p<0.05.
Results
Compared to vehicle controls, EAE mice receiving pas-
sively transferred NMO-IgG developed significantly worse
EAE scores within 24 hours of injection and remained sta-
bly worse for 2 months (Figure 1A). EAE mice passively
transferred with control-IgG similarly worsened in the first
24 hours but recovered to EAE scores similar to vehicle-
treated controls over the next two months (Figure 1B).
Exacerbated weight loss persisted in the NMO-IgG-treated
mice during the 2-month experiment, thus reflecting the
worsening EAE scores during that time period (Figure 1C).
To determine the target(s) of human IgG injected into
EAE mice, we sacrificed a cohort of mice 24 hours after
the final of four intraperitoneal injections and stained
tissue sections for anti-human antibody. In addition to
positive staining in non-CNS tissue such as the lung and
kidney, we found significant levels of anti-human anti-
body staining in the spinal cord and optic nerve, which
are the predominant sites of NMO disease in humans
(Figure 2A). The control-IgG was also found in the CNS,
but largely in the meninges and not within the parenchyma
of the spinal cord (Figure 2B). Co-staining with anti-AQP4
revealed colocalization with anti-human antibody, espe-
cially around blood vessels and in the pia-glia limitans of
the spinal cord (Figures 2C-E). This suggests that human
NMO-IgG antibodies injected intraperitoneally can reach
their target in the spinal cord of inflamed mouse spinal
cord in EAE. Forty-three days following the last intraperi-
toneal injection of NMO or control-IgG, staining for hu-
man IgG in the spinal cords was indistinguishable from
vehicle control mice (injected with PBS), confirming that
the human antibodies were removed from circulation.
Sixty-two days after induction of EAE, 43 days follow-
ing the last IgG infusion, the group that received the
NMO-IgG had numerous large subpial demyelinated le-
sions that were located in the lateral and ventral columns
of the spinal cord (Figure 3). Vehicle and control-IgG
treated animals had typical demyelinated lesions which ex-
tended into the deeper white matter areas, in contrast to
NMO-IgG lesions that seemed to be bordered primarily by
the pia. Aquaporin-4 staining of these sections revealed
homogenous staining but with an increase in AQP4-
immunoreactivity in areas of demyelination in all three
groups (Figure 3).
The overall proportion of demyelinated area was not
significantly different between the 3 groups (NMO-
Table 1 Details of the primary antibody reagents used for immunohistochemical experiments in these studies
Primary antibody Antigenic target Concentration Blocking solution Manufacturer Catalog number
Anti-Aquaporin 4, C-terminus Aquaporin-4 1:200 5% BSA-PBS + 1:100 NGS +
0.1% Triton X-100
Millipore AB3594-200UL
Purified Rat anti-mouse CD45 All cells of hematopoietic origin,
except erythrocytes
1:50 5% BSA-PBS + 1:100 NGS BD Pharmingen 550539
Purified Rat anti-mouse CD5 Thymocytes, T lymphocytes, thymic
NK-T cells, subset of B lymphocytes
1:50 5% BSA-PBS + 1:100 NGS +
0.1% Triton X-100
BD Pharmingen 553017
Purified Rat anti-mouse CD45R
(B220)
B lymphocytes 1:50 5% BSA-PBS + 1:100 NGS +
0.1% Triton X-100
BD Pharmingen 550286
Purified Rat anti-mouse Ly-6G
and Ly-6C
Granulocytes 1:50 5% BSA-PBS + 1:100 NGS +
0.1% Triton X-100
BD Pharmingen 550291
Purified Goat anti-human Human IgG 1:250 5% BSA-PBS + 1:100 NGS Invitrogen A-11013
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IgG vs. CTL-IgG p=0.43, vs. Vehicle p=0.70). However,
there were a significantly greater number of large lesions
(defined as ≥10,000 μm2) that were primarily subpial in
the NMO group (5.4± 1.2) compared to the control-IgG
(2.0± 0.0) or the vehicle control group (2.0± 1.2) (p=0.048
and 0.049 respectively; Figure 4C). When expressed as a
percentage of the total demyelinated area, large subpial
lesions comprised a greater proportion of the lesioned
area in the NMO-IgG group (39.0 ± 3.5%) than in the
control-IgG (18.9 ± 5.1%) or the vehicle-treated group
(11.8 ± 7.0%) (p<0.008 and p<0.005 respectively) (Figure 4).
Considering pial lesions of all sizes, 72.9 ± 3.8% of all
demyelinated area in the NMO-IgG group was subpial
compared to 39.9 ±16.7% in the control-IgG group (p=0.02
vs. NMO-IgG) and 40.6 ± 11.5% in the vehicle control
group (p=0.02 vs. NMO-IgG). Simply injecting non-
specific IgG into mice did not alter lesion localization,
since the pattern of demyelination in the control-IgG and
vehicle control groups were not significantly different
from each other (p=0.97).
Similar to the spinal cord, optic nerves from the NMO-
IgG-treated group showed subpial demyelinating lesions
(Figure 5). The control-IgG and vehicle control groups also
had occasional areas of demyelination in the optic nerve
and quantitative comparison proved difficult with this
small amount of optic nerve tissue. As in the spinal cord,
AQP4 staining of optic nerve sections revealed normal
homogenous staining of all sections with an increase in
staining in areas of demyelination in all three groups
(Figure 5).
In most models of rodent EAE, the majority of white
blood cells in CNS lesions are T-cells, while human NMO
pathology is characterized by the presence of granu-
locytes, including neutrophils and eosinophils in demye-
linating lesions, along with T cells, a few B-cells, and
macrophages. We found that several early (20 days post-
immunization) lesions in the NMO-IgG-treated group
developed lesions that were infiltrated by granulocytes
in addition to typical EAE lesions identified by T cells
(Figure 6). The spinal cords of control-IgG treated mice
showed sporadic granulocytes, although not in high num-
bers or in a perivascular distribution. While further study
is needed to quantify the granulocyte infiltration, it appears
that granulocytes within EAE lesions may have contributed
to the worsening of both the NMO and control-IgG
groups. At 62 days after immunization, rare inflam-
matory EAE lesions in all three groups were still evident
with typical infiltration by T-cells, but granulocytes were
no longer present.
Discussion
Our mouse model of NMO resembles human NMO in
several ways. First, the neurological phenotype of mouse
EAE worsens in the presence of NMO-IgG and remains
Figure 1 Experimental autoimmune encephalomyelitis (EAE)
with passive transfer of the NMO-IgG, control IgG and vehicle
saline control. (A) EAE scores comparing mice receiving NMO-IgG
(diamonds, black line) versus vehicle saline control (squares, grey
line) with 4 injections on days 13, 14, 18, and 19 as indicated by the
black arrows. EAE scores were statistically different starting from day
15 post-immunization. (B) EAE scores comparing mice receiving the
NMO-IgG (diamonds, black line) versus control IgG (circles, black line).
EAE scores were statistically different starting from day 25 post-
immunization. (C) Weight of NMO-IgG mice (diamonds, black line),
control IgG mice (circles, dashed line) and vehicle saline control mice
(squares, grey line) during course of EAE. Sample size = 10 mice in
the NMO group, 9 in the vehicle contorl group, 5 in the control IgG
group. Experiment repeated with similar results.
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persistently worse for the duration of our 2-month study.
This correlates with large subpial demyelinated lesions in
the spinal cord. Second, the optic nerves and spinal cord
are the predominant sites of pathology, similar to human
NMO disease. Thirdly, pathologic evaluation of EAE mice
exposed to NMO-IgG showed evidence of infiltration by
granulocytes in acute lesions.
In the context of ameliorating NMO severity, one may
conclude from this study that NMO-IgG may be harm-
ful when present in acute inflammatory lesions of the
CNS and should be targeted for removal. Data on pa-
tients is mixed with regards to the correlation of NMO-
IgG titer with either the severity of an acute attack or the
degree of recovery following treatment [10,11]. However,
there is good evidence that presence of the NMO-IgG is
predictive of more frequent relapses and a worse neuro-
logic outcome [8], the latter of which we observed in our
mouse model.
There has been debate on the role of the NMO-IgG as
a pathogenic antibody versus a biomarker of disease
[12-14]. In our model, there is strong evidence in favor
of the NMO-IgG as a contributor to the neurological
pathology and behavioral outcome. As in rat models of
NMO [5,6], there is no effect of the NMO-IgG in the ab-
sence of EAE in this strain of mouse and there is no
penetration of NMO-IgG into the CNS parenchyma in
the absence of EAE. However, NMO-IgG appears to
convert the pathology and disease course in mice from
acute behavioral disease with small lesions within super-
ficial white matter of the dorsal columns to confluent
pial lesions in the dorsal and lateral spinal cord. Al-
though the total demyelination is similar, large confluent
lesions involving the dorsolateral corticospinal tracts
may lead to greater disability in this mouse model. We
also found limited evidence for perivascular granulocyte
recruitment in the NMO-IgG treated animals but the
role of these cells in altering the distribution of lesions
and in causing persistent behavioral disease in our EAE
mice needs further study. Our hypothesis is that NMO-
IgG targets AQP4, which is preferentially expressed on
the astrocytic foot processes of the pia-glia limitans. As
a result of the antibody binding, a humoral-mediated in-
flammatory process ensues that includes granulocyte in-
filtration. It is temporary because the human NMO-IgG
is cleared shortly after passive transfer. Interestingly, while
behavioral disease persisted for 2 months, human IgG and
granulocytes were not detectable in the CNS at the 2-
month time point. This suggests that transient exposure to
the NMO-IgG has long-lasting consequences. This might
explain why NMO-IgG titer is not easily linked to disease
Figure 2 Spinal cord sections from mouse 24 hours after 4 injections of NMO-IgG on days 13, 14, 18, and 19 (A) versus control IgG
(B) showing NMO-IgG penetration into the parenchyma of the spinal cord as shown by anti-human IgG staining (green). Sections were
costained with anti-human IgG (green, C), anti-AQP4 antibody (red, D) showing co-localization in areas of AQP4 expression especially around
blood vessels (arrow in merged image, E).
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severity: transient spikes in titer coinciding with blood–
brain permeability in the spinal cord and optic nerve may
cause tissue damage and disease, but the overlap of these
two events may be rare.
In contrast to our mouse model, rats with EAE that
received control-IgG did not manifest behavioral wors-
ening defined as a higher EAE disability score [5,6]. In
addition, some patients’ NMO-IgG have more toxic po-
tential than others [15]. While this may be due to the
presence of autoantibodies, which are not reactive to the
animal model species being used, it is still unclear as to
why we observed transient worsening of behavioral signs
in EAE mice injected with the control-IgG [16]. The pa-
tient we isolated our control-IgG from suffered from
chronic kidney disease that required plasma exchange to
remove ABO incompatible antibodies from circulation
prior to kidney transplant. In addition to not being posi-
tive for AQP4-immunoreactivity, we found no evidence
of other autoantibodies binding to antigens in the mouse
CNS. The observed transient worsening in mice receiv-
ing the control-IgG did not significantly alter the distri-
bution of lesions as did the NMO-IgG. Because this
worsening was not observed in rat models of EAE, this
effect of control-IgG could be unique to this patient’s
IgG. The difference in rodent species could also influence
the course of EAE and reactivity of autoantibodies.
Another difference between this mouse NMO model
and the previous rat NMO models is that the behavioral
worsening in our mouse model was not accompanied by
AQP4 depletion. This could mean that higher EAE
Figure 3 Sections from spinal cords of mice 62 days after injection of NMO-IgG (A, D, G), human IgG controls (B, E, H) and vehicle
saline controls (C, F, I). Eriochrome staining shows large areas of pale blue demyelination in the NMO-IgG group (A, magnified in D) as
indicated by the arrows. Typical EAE areas of posterior column demyelination were present in the control-IgG (B, magnified in E) and vehicle
control (C, magnified in F) groups. Aquaporin-4 staining (red) in all groups were similar and appeared increased in areas of demyelination. Scale
bars in D-I represent 100 μm.
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Figure 4 Quantification and characterization of demyelinated lesions in the spinal cord were based on manual outlines of the total
myelinated area (blue) and the demyelinated area (red/yellow) as shown in A. The number of pial lesions greater than 10,000 μm2 made
up nearly 40% of all the demyelinated lesions in the NMO-IgG group (B). In addition, the total number of pial lesions in each NMO-IgG mouse on
average was higher (C). Accounting for pial lesions of all sizes, the NMO-IgG group had almost double the number compared to the control-IgG
and vehicle groups (D).
Figure 5 Optic nerve sections were stained for myelin by eriochrome (blue stain) and AQP4 expression 62 days after injection of
human IgG or saline. The mice that received injections of NMO-IgG show areas of pale blue demyelination (arrows in A). The control-IgG
group had some demyelination in the optic nerves (arrows in B) and vehicle controls had only few visible demyelinating lesions (panel C).
Similar to the spinal cord, AQP4 staining (anti-AQP4, Santa Cruz, white) was increased in all groups in areas of demyelination (sections D-F).
Scale bars represent 100 μm.
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disability score with NMO-IgG does not require overt
depletion of astrocytes or of AQP4 from lesions but does
not rule out AQP4 involvement. Interestingly, even se-
vere depletion of AQP4 and astrocytes from lesioned
areas in rat animal models does not lead to myelin dam-
age, suggesting that myelin can survive at least transient
loss of AQP4. The long term consequences of short
term NMO-IgG exposure in rat models has not yet been
reported. Also, purified preparations of NMO-IgG have
been difficult to obtain due to the polyclonal nature of
the antibody and the uncertainty about which antigenic
targets on AQP4 are important in the pathogenesis of
disease [17]. Further work in this area will allow better
specificity of passive transfer studies in NMO.
Conclusions
In this experimental model of EAE in C57/BL6 mice in
which passively transferred IgG from NMO patients is
infused at onset of neurologic disease, we conclude that
the anti-AQP4 antibody contributes to the pathogenicity
by targeting subpial astrocytes leading to large, confluent
demyelinated lesions in the spinal cord and optic nerve.
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